Elicera Therapeutics AB (FRA:8E8) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8E8 Elicera Therapeutics AB FRA:8E8
40 GF Score
Price €0.21
! 1 Warning Sign
View Full Analysis

What is Elicera Therapeutics AB Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Elicera Therapeutics AB's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:8E8 vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Elicera Therapeutics AB's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Elicera Therapeutics AB Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Elicera Therapeutics AB's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Elicera Therapeutics AB's Margin of Safety % (DCF Earnings Based) falls into.


FRA:8E8
40GF Score
Elicera Therapeutics AB FRA:8E8
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elicera Therapeutics AB Business Description

Other Exchanges ELIC:Sweden
Address Massans gata 10, World Trade Center Goteborg, 7th Floor, Goteborg, SWE, 412 51
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. Its product portfolio consists of four drug candidates, including two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to the universal CAR T-cell technology platform, iTANK (ELC-001). The Company is running four internal immunotherapy development projects, comprising two CAR T-cell programs and two oncolytic virus programs.
40GF Score

Get the complete analysis for FRA:8E8

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.21
Price